The US Food and Drug Administration recently issued three drug GMP warning letters to drug repackers of active pharmaceutical ingredients for omitting the name of the original manufacturers of the active pharmaceutical ingredients to customers, a common practice in the API sector that the agency wants to stop.
The three repackers were all in the US: B&B Pharmaceuticals in Englewood, CO; Asclemed USA, also known as Enovachem, in Torrance, CA; and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?